You just read:

Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program

News provided by

Eiger BioPharmaceuticals, Inc.

Nov 14, 2016, 08:00 ET